As it was clearly elucidated in Supplementary Figures 2 and 3, IL-22 gene therapy was initiated in mice with established nephropathy and continued for 12 weeks to determine the therapeutic effects of IL-22 on the progression of DKD. The gene discussed is IL22; the disease is diabetic kidney disease.